153 related articles for article (PubMed ID: 31488360)
1. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
Weller J; Tzaridis T; Mack F; Steinbach JP; Schlegel U; Hau P; Krex D; Grauer O; Goldbrunner R; Bähr O; Uhl M; Seidel C; Tabatabai G; Brehmer S; Bullinger L; Galldiks N; Schaub C; Kebir S; Stummer W; Simon M; Fimmers R; Coch C; Glas M; Herrlinger U; Schäfer N
Lancet Oncol; 2019 Oct; 20(10):1444-1453. PubMed ID: 31488360
[TBL] [Abstract][Full Text] [Related]
2. Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.
Pollom EL; Fujimoto D; Wynne J; Seiger K; Modlin LA; Jacobs LR; Azoulay M; von Eyben R; Tupper L; Gibbs IC; Hancock SL; Li G; Chang SD; Adler JR; Harsh GR; Harraher C; Nagpal S; Thomas RP; Recht LD; Choi CYH; Soltys SG
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):123-130. PubMed ID: 28586949
[TBL] [Abstract][Full Text] [Related]
3. Radiation and concomitant chemotherapy for patients with glioblastoma multiforme.
Villà S; Balañà C; Comas S
Chin J Cancer; 2014 Jan; 33(1):25-31. PubMed ID: 24325790
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of diffusion MRI-based parametric response mapping for prognosis and treatment response in glioblastoma.
Rydelius A; Bengzon J; Engelholm S; Kinhult S; Englund E; Nilsson M; Lätt J; Lampinen B; Sundgren PC
Magn Reson Imaging; 2023 Dec; 104():88-96. PubMed ID: 37734574
[TBL] [Abstract][Full Text] [Related]
5. ELEVATE - evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial.
Smyth E; Cozens K; Griffiths D; Clark KL; Ewings S; Petty R; Underwood T; Fitzgerald RC; Tanner J; Giger O; Anand S; Griffiths G
BMC Cancer; 2022 Sep; 22(1):946. PubMed ID: 36050653
[TBL] [Abstract][Full Text] [Related]
6. Treatment-associated imaging changes in newly diagnosed MGMT promoter-methylated glioblastoma undergoing chemoradiation with or without cilengitide.
Flies CM; Friedrich M; Lohmann P; van Garderen KA; Smits M; Tonn JC; Weller M; Galldiks N; Snijders TJ
Neuro Oncol; 2024 May; 26(5):902-910. PubMed ID: 38219019
[TBL] [Abstract][Full Text] [Related]
7. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.
Ardon H; Van Gool SW; Verschuere T; Maes W; Fieuws S; Sciot R; Wilms G; Demaerel P; Goffin J; Van Calenbergh F; Menten J; Clement P; Debiec-Rychter M; De Vleeschouwer S
Cancer Immunol Immunother; 2012 Nov; 61(11):2033-44. PubMed ID: 22527250
[TBL] [Abstract][Full Text] [Related]
8. Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
Lesueur P; Lequesne J; Grellard JM; Dugué A; Coquan E; Brachet PE; Geffrelot J; Kao W; Emery E; Berro DH; Castera L; Goardon N; Lacroix J; Lange M; Capel A; Leconte A; Andre B; Léger A; Lelaidier A; Clarisse B; Stefan D
BMC Cancer; 2019 Mar; 19(1):198. PubMed ID: 30832617
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of anlotinib combined with the STUPP regimen in patients with newly diagnosed glioblastoma: a multicenter, single-arm, phase II trial.
Lai S; Li P; Liu X; Liu G; Xie T; Zhang X; Wang X; Huang J; Tang Y; Liu Z; Shen G; Li C; Lu F; Wang L; Jiang F; Sun C; Chen Y; Chen M
Cancer Biol Med; 2024 Mar; 21(5):433-44. PubMed ID: 38445445
[TBL] [Abstract][Full Text] [Related]
10. Autologous cell immunotherapy (IGV-001) with IGF-1R antisense oligonucleotide in newly diagnosed glioblastoma patients.
Lee IY; Hanft S; Schulder M; Judy KD; Wong ET; Elder JB; Evans LT; Zuccarello M; Wu J; Aulakh S; Agarwal V; Ramakrishna R; Gill BJ; Quiñones-Hinojosa A; Brennan C; Zacharia BE; Silva Correia CE; Diwanji M; Pennock GK; Scott C; Perez-Olle R; Andrews DW; Boockvar JA
Future Oncol; 2024 Mar; 20(10):579-591. PubMed ID: 38060340
[TBL] [Abstract][Full Text] [Related]
11. Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial.
Le Rhun E; Gorlia T; Felsberg J; Jongen J; Maurage CA; Ducray F; Gramatzki D; Hau P; Chinot OL; Preusser M; Cartalat S; Roth P; van den Bent M; Furtner J; Collienne M; Reifenberger G; Weller M
Eur J Cancer; 2024 Feb; 198():113475. PubMed ID: 38159337
[TBL] [Abstract][Full Text] [Related]
12. Glioblastoma and Other Primary Brain Malignancies in Adults: A Review.
Schaff LR; Mellinghoff IK
JAMA; 2023 Feb; 329(7):574-587. PubMed ID: 36809318
[TBL] [Abstract][Full Text] [Related]
13. Reverse swing-M, phase 1 study of repurposing mebendazole in recurrent high-grade glioma.
Patil VM; Bhelekar A; Menon N; Bhattacharjee A; Simha V; Abhinav R; Abhyankar A; Sridhar E; Mahajan A; Puranik AD; Purandare N; Janu A; Ahuja A; Krishnatry R; Gupta T; Jalali R
Cancer Med; 2020 Jul; 9(13):4676-4685. PubMed ID: 32400117
[TBL] [Abstract][Full Text] [Related]
14. A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.
Brandes AA; Carpentier AF; Kesari S; Sepulveda-Sanchez JM; Wheeler HR; Chinot O; Cher L; Steinbach JP; Capper D; Specenier P; Rodon J; Cleverly A; Smith C; Gueorguieva I; Miles C; Guba SC; Desaiah D; Lahn MM; Wick W
Neuro Oncol; 2016 Aug; 18(8):1146-56. PubMed ID: 26902851
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma.
Kobayashi N; Takeda Y; Okubo N; Suzuki A; Tokuhisa M; Hiroshima Y; Ichikawa Y
Cancer Sci; 2021 May; 112(5):1936-1942. PubMed ID: 33453146
[TBL] [Abstract][Full Text] [Related]
16. A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial.
von Arx C; Della Vittoria Scarpati G; Cannella L; Clemente O; Marretta AL; Bracigliano A; Picozzi F; Iervolino D; Granata V; Modica R; Bianco A; Mocerino C; Di Mauro A; Pizzolorusso A; Di Sarno A; Ottaiano A; Tafuto S;
ESMO Open; 2024 May; 9(5):103003. PubMed ID: 38615472
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy-induced glioblastoma: distinct differences in overall survival, tumor location, pMGMT methylation and primary tumor epidemiology in Hong Kong chinese patients.
Woo PYM; Lee JWY; Lam SW; Pu JKS; Chan DTM; Mak CHK; Ho JMK; Wong ST; Po YC; Lee MWY; Chan KY; Poon WS
Br J Neurosurg; 2024 Apr; 38(2):385-392. PubMed ID: 33576706
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life and neurocognitive functioning in patients with recurrent glioblastoma treated with intracerebral immune checkpoint inhibition.
Geens W; Vanlaer N; Nijland L; Van Laere S; Schwarze JK; Bruneau M; Neyns B; Rogiers A; Duerinck J
J Neurooncol; 2024 May; 168(1):159-169. PubMed ID: 38502281
[TBL] [Abstract][Full Text] [Related]
19. Glioblastoma in elderly patients: solid conclusions built on shifting sand?
Wick A; Kessler T; Elia AEH; Winkler F; Batchelor TT; Platten M; Wick W
Neuro Oncol; 2018 Jan; 20(2):174-183. PubMed ID: 29016815
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
